Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024BMJOpen Access

6ER-037 Pharmaco-utilisation of ibrutinib in CLL: a single centre study

View Full Paper
Ask AI
Bookmark
Share

Authors

GFG FaitelliAUAndrealuna UccieroAPAlessia Pisterna

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Faitelli et al. (2024) studied this question.

synapsesocial.com/papers/68e7660bb6db6435876db9e5https://doi.org/10.1136/ejhpharm-2024-eahp.499
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long‐Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib2026
  2. 25PSQ-038 Real-world safety of ibrutinib in clinical practice in patients with chronic lymphocytic leukaemia2024
  3. 3A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)2024 · 1 citations
  4. 4Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre <scp>REALITY</scp> study2024 · 4 citations
  5. 55PSQ-104 Real-world evidence: is ibrutinib as safe as evidence tells?2024 · 1 citations